10.1161/HYPERTENSIONAHA.118.10900 69 de JongD
BPC-157 is commonly described in research literature as a stable gastric pentadecapeptide and is studied in laboratory models involving gastric tissue, epithelial integrity, angiogenesis, tendon and ligament response, soft-tissue repair models, inflammation pathways and wound-healing research
Compact, portable, and easy to use, its perfect for researchers seeking simplicity and accuracy
In the STEP-1 obesity trial, semaglutide 2.4 mg weekly produced roughly 14.9% mean body-weight loss over 68 weeks ( Wilding et al., NEJM 2021 )
Warning Not suitable for children, pregnant and lactating women